Loss of diphthamide pre-activates NF-κB and death receptor pathways and renders MCF7 cells hypersensitive to tumor necrosis factor
- Sebastian Stahla,
- Ana Rita da Silva Mateus Seidlb,
- Axel Ducretc,
- Sabine Kux van Geijtenbeekc,
- Sven Michelc,
- Tomas Racekd,
- Fabian Birzeled,
- Alexander K. Haasa,
- Ruediger Ruegerd,
- Michael Gerge,
- Gerhard Niederfellnerb,
- Ira Pastanf,1, and
- Ulrich Brinkmanna,1
- aRoche Pharma Research & Early Development, Large Molecule Research, Roche Innovation Center Penzberg, 82377 Penzberg, Germany;
- bRoche Pharma Research & Early Development, Discovery Oncology, Roche Innovation Center Penzberg, 82377 Penzberg, Germany;
- cRoche Pharma Research & Early Development, Pharmaceutical Sciences, Translational Technology and Bioinformatics, Roche Innovation Center Basel, 4070 Basel, Switzerland;
- dRoche Pharma Research & Early Development, Pharmaceutical Sciences, Translational Technology and Bioinformatics, Roche Innovation Center Penzberg, 82377 Penzberg, Germany;
- eRoche Diagnostics, Roche Professional Diagnostics, Biological Rare Reagents, 82377 Penzberg, Germany;
- fLaboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda MD 20892-4263
-
Contributed by Ira Pastan, July 2, 2015 (sent for review June 4, 2015); reviewed by Tadashi Yamamoto and Francesco Blasi
Significance
Diphthamide is a conserved modification on eukaryotic translation elongation factor 2 (eEF2). Analyses of genetically defined diphthamide-deficient cell lines indicate that this modification determines not only sensitivity of cells to the ADP-ribosylating toxins Pseudomonas exotoxin A and diphtheria toxin, but it also modulates nuclear factor of kappa light polypeptide gene enhancer in B cells (NF-κB) and TNF receptor signaling pathways.
Abstract
The diphthamide on human eukaryotic translation elongation factor 2 (eEF2) is the target of ADP ribosylating diphtheria toxin (DT) and Pseudomonas exotoxin A (PE). This modification is synthesized by seven dipthamide biosynthesis proteins (DPH1–DPH7) and is conserved among eukaryotes and archaea. We generated MCF7 breast cancer cell line-derived DPH gene knockout (ko) cells to assess the impact of complete or partial inactivation on diphthamide synthesis and toxin sensitivity, and to address the biological consequence of diphthamide deficiency. Cells with heterozygous gene inactivation still contained predominantly diphthamide-modified eEF2 and were as sensitive to PE and DT as parent cells. Thus, DPH gene copy number reduction does not affect overall diphthamide synthesis and toxin sensitivity. Complete inactivation of DPH1, DPH2, DPH4, and DPH5 generated viable cells without diphthamide. DPH1ko, DPH2ko, and DPH4ko harbored unmodified eEF2 and DPH5ko ACP- (diphthine-precursor) modified eEF2. Loss of diphthamide prevented ADP ribosylation of eEF2, rendered cells resistant to PE and DT, but does not affect sensitivity toward other protein synthesis inhibitors, such as saporin or cycloheximide. Surprisingly, cells without diphthamide (independent of which the DPH gene compromised) were presensitized toward nuclear factor of kappa light polypeptide gene enhancer in B cells (NF-κB) and death-receptor pathways without crossing lethal thresholds. In consequence, loss of diphthamide rendered cells hypersensitive toward TNF-mediated apoptosis. This finding suggests a role of diphthamide in modulating NF-κB, death receptor, or apoptosis pathways.
Footnotes
- ↵1To whom correspondence may be addressed. Email: pastani{at}mail.nih.gov or ulrich.brinkmann{at}roche.com.
-
Author contributions: S.S., G.N., I.P., and U.B. designed research; S.S., A.R.d.S.M.S., A.D., S.K.v.G., T.R., A.K.H., and M.G. performed research; A.R.d.S.M.S., A.D., S.K.v.G., S.M., R.R., and M.G. contributed new reagents/analytic tools; S.S., A.R.d.S.M.S., A.D., S.K.v.G., S.M., T.R., F.B., G.N., I.P., and U.B. analyzed data; and S.S., I.P., and U.B. wrote the paper.
-
Reviewers: F.B., Fondazione Italiana per la Ricerca sul Cancro Institute of Molecular Oncology; and T.Y., Okinawa Institute of Science and Technology Graduate University.
-
Conflict of interest statement: S.S., A.R.d.S.M.S., A.D., S.K.G., S.M., T.R., F.B., A.K.H., R.R., M.G., G.N., and U.B. are employed by Roche, and I.P. by the National Cancer Institute. All parties are interested in and hold patents (I.P.’s patent has been assigned to the NIH and he has a Cooperative Research and Development Agreement with Roche Pharmaceuticals) for the development of Pseudomonas exotoxin-derived entities in targeted cancer therapy.
-
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1512863112/-/DCSupplemental.
Freely available online through the PNAS open access option.



